Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Adarotene is an atypical retinoid.1 It does not induce RARα or RAR-mediated transcription in a luciferase assay. It inhibits proliferation of a variety of cancer cells, including mutant p53-containing DU145 prostate, A431 cervical, and Me665/2/21 melanoma cancer cells (IC50s = 0.1, 0.25, and 0.25 µM, respectively) and wild-type p53-containing LNCaP prostate, H460 non-small cell lung, and HCT116 colon cancer cells (IC50s = 0.12, 0.19, and 0.32 µM, respectively). Adarotene induces DNA damage in wild-type p53-containing IGROV-1 cells and apoptosis in IGROV-1 and DU145 cells. It reduces tumor burden and increases survival in a mouse model of chronic myeloid leukemia (CML) when administered at a dose of 15 mg/kg per day.2
WARNING This product is not for human or veterinary use.
1. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J. Med. Chem. 46(6), 909-912 (2003).
2. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model. Int. J. Cancer 137(3), 698-709 (2015).